CHINARES PHARMA (03320) is potentially selling about 17.87% equity in Tianmai Biotechnology.

19:47 09/02/2026

China Resources Medical (03320) announced that its wholly-owned subsidiary, China Resources Medical Investment Co., Ltd. (CRM Investment), has initiated the potential sale of approximately 17.87% equity interest in Hefei Tianmai Biotech Development Co., Ltd. (Tianmai Biotech) held by CRM Investment and its subsidiaries. The potential sale will be publicly listed on the Shanghai United Property Exchange, with a minimum listing price of approximately RMB 1.42 billion. As of the date of this announcement, CRM Investment and its subsidiaries hold less than 30% equity interest in Tianmai Biotech.

CHINARES PHARMA (03320) announced that its wholly-owned subsidiary CHINARES PHARMA Investment Limited (CHINARES PHARMA Investment) has initiated the potential sale of approximately 17.87% equity in Hefei Tianmai Biotechnology Development Co., Ltd (Tianmai Biotechnology), held by CHINARES PHARMA Investment and its subsidiaries. The potential sale will be publicly listed on the Shanghai United Property Exchange, with a reserve price of approximately RMB 1.42 billion. As of the date of this announcement, CHINARES PHARMA Investment and its subsidiaries hold less than 30% equity in Tianmai Biotechnology.

CHAOWEI POWER (00951): Executive Director Zhou Longrui Passed Away

SHOUHUI GROUP (02621) spent HK$15,400 to repurchase 4,400 shares on February 9.

Chengdu B-ray Media (600880.SH) plans to acquire a 9% stake in its subsidiary Red Star Education.

CHAOWEI POWER (00951): Executive Director Zhou Longrui Passed Away

SHOUHUI GROUP (02621) spent HK$15,400 to repurchase 4,400 shares on February 9.

Chengdu B-ray Media (600880.SH) plans to acquire a 9% stake in its subsidiary Red Star Education.